Five patients harboring a programmed death ligand 1/2 (PD-L1/-L2) amplification, TMB-high, breast cancer gene 2 (BRCA2) mutation or ERBB2 amplification were treated with each investigational drug. Here, ERBB2 is linked to cancer.